Nimotuzumab for the first line treatment of metastatic pancreatic cancer
Status In progress
Decision Selected
Process STA pre-2018

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Executive Lead: TBC
Project manager:

Bijal Joshi

Technical Lead: TBC


Key events during the development of the guidance:

Date Update
19 September 2014 Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.

For further information on our processes and methods, please see our CHTE processes and methods manual